A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers

A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers

Abstract Background Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment...

Full description

Bibliographic Details
Main Authors: Laura B. Oswald, Brandy Arredondo, Mika Kadono, Dinorah Martinez‐Tyson, Cathy D. Meade, Frank Penedo, Michael H. Antoni, Hatem Soliman, Ricardo L. B. Costa, Heather S. L. Jim
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Cancer Medicine
Subjects:
breast neoplasms
neoplasm metastasis
patient‐reported outcomes measures
psycho‐oncology
qualitative research
quality of life
Online Access:https://doi.org/10.1002/cam4.4055

Internet

https://doi.org/10.1002/cam4.4055

Similar Items